Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
EXCH
BUKWANG PHARMACEUTICAL IND
★
BUKWANG PHARMACEUTICAL Holds IR Meeting for Q1 2026 Earnings and R&D Update
16h ago
EXCH
BUKWANG PHARMACEUTICAL IND
★
Latuda Adjunctive Therapy for MDD Phase 3 IND Approved, Expansion of Indication Expected
06/02/2026, 06:34 PM
EXCH
BUKWANG PHARMACEUTICAL IND
★
BUKWANG Corporate Governance Report: Enhanced Shareholder Returns via Share Cancellation and Dividend Increase, Rights Offering and Acquisition for Growth
06/01/2026, 04:56 PM
FTC
BUKWANG PHARMACEUTICAL IND
★
BUKWANG PHARMACEUTICAL, Routine OCI Group Status Disclosure... Stable Financial Structure, No Material Changes
05/29/2026, 02:18 PM
EXCH
BUKWANG PHARMACEUTICAL IND
★
Acquisition of 74.97% Stake in Korea Union Pharmaceutical for 30 Billion Won via Third-Party Allotment
05/16/2026, 07:51 PM
PERI
BUKWANG PHARMACEUTICAL IND
★
Bukwang Pharm 2026 Q1: Operating Profit Down but Dividend Maintained, R&D Pipeline Progressing
05/14/2026, 04:35 PM
EXCH
BUKWANG PHARMACEUTICAL IND
★
Acquisition of Stake in Financially Weak Company
05/13/2026, 02:30 PM
EXCH
BUKWANG PHARMACEUTICAL IND
★
IR Meeting for 2025 Q4 Results and R&D Progress
05/10/2026, 07:00 PM